EFFECT OF ORALLY ADMINISTERED ANTITHYROID THIOUREYLENES ON PCNA AND P53 EXPRESSION IN PSORIATIC LESIONS

Abstract

Since PCNA is a marker of cellular proliferation and p53 inhibits cellular cycling, some of the beneficial effects of PTU and MMI in psoriasis may depend on the ability of the drugs to impair cellular turnover, perhaps by binding to the triiodothyronine (T3) receptor. These effects may be in addition to the previously described effects of PTU and MMI as immune modulators and free radical scavengers.